Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration

By D. Dickson, C. Bergeron, S. Chin, C. Duyckaerts, D. Horoupian, K. Ikeda, K. Jellinger, P. Lantos, C. Lippa, S. Mirra and 4 more. Journal of Neuropathology and Experimental Neurology, 2002

684 citations recorded by the source corpus.

Subfields: Neurology, Physiology

View Paper: https://www.semanticscholar.org/paper/806fe37e69ec632dfd4c5ed5255d2fe51047cda5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

In Physiology

Citations in the corpus

Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration (2007, background): “tau-positive, and tau-positive neuroWbrillary tangles in the neocortex, basal ganglia, and brainstem nuclei [24, 27].”
Criteria for the diagnosis of corticobasal degeneration (2013, background): “As a pathologic diagnosis, CBD is characterized by widespread deposition of hyperphosphorylated 4-repeat tau in neurons and glia, the latter as astrocytic plaques, in specific topographic areas.(3) Despite various clinical diagnostic criteria (table e-1 on the Neurology® Web site at www.”
Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. (2006, background): “, 2005), five had CBD (Dickson et al., 2002), five had FTLD with ubiquitin-only-immunoreactive changes (FTLD-U) (Lowe and Rossor, 2003; Josephs et al.”
Prevalence of Amyloid PET Positivity in Dementia Syndromes (2015, neutral): “Age, median (range), y 69 (38-95) 66 (41-85) 75 (46-90) 68 (55-87) 68 (40-88) 68 (40-88)”
The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy (2015, methodology): “In the 15 other tauopathy cases (cases submitted for review with diagnoses other than CTE) (Supplementary Table 2), the reviewers generally agreed with the submission diagnoses of AD (97.1 % of responses), CBD (92.8 %), and PART (78.5 %); however, there were frequent discrepancies in cases with the ”
Parkinson's disease and parkinsonism: neuropathology. (2012, background): “Cortical neurons in affected areas have pleomorphic tau-immunoreactive inclusions, and there are invariably numerous tau positive threads in both gray and white matter of affected cortices, as well as in the basal ganglia (Dickson et al. 2002).”
Pathology of Neurodegenerative Diseases. (2017, background): “Neuropathologic criteria for CBD require neuronal, glial, and thread pathology in the gray and white matter of cortical and subcortical areas (Dickson et al. 2002).”
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. (2016, background): “…of Alzheimer’s disease’; Gorno-Tempini et al., 2011), corticobasal syndrome (Alzheimer’s disease path- ology is the causative pathology in up to 25% of cases; Dickson et al., 2002; Lee et al., 2011), and memory- predominant and behavioural/dysexecutive variants of Alzheimer’s disease…”